Antimicrobial Agents and Chemotherapy · 2017 · 105 citations · 15 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance EvolutionAntibiotic Resistance MechanismsCarbapenem ResistanceMultidrug ResistanceCarbapenem AntibioticsCarbapenem Resistance MechanismsKlebsiella Pneumoniae CarbapenemaseKlebsiella Pneumoniae ResistanceMolecular Evolution Of PathogensPorin Mutation ResistancePorin ProteinsSubstitutions
ABSTRACT Ceftazidime-avibactam resistance is mediated by bla KPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different bla KPC-3 mutations ( n = 5) or wild-type bla KPC-3 ( n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, bla KPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.
15
Ryan K. Shields, Liang Chen, Shaoji Cheng et al. · Antimicrobial Agents and Chemotherapy · 2016 · 485 citations · Full text
Ryan K. Shields, Brian A. Potoski, Ghady Haidar et al. · Clinical Infectious Diseases · 2016 · 428 citations · Full text
Yu-Kuo Tsai, Chang‐Phone Fung, Jung‐Chung Lin et al. · Antimicrobial Agents and Chemotherapy · 2011 · 337 citations · Full text